function and adipocytokine release from adipose tissue). Inadequateness in resembling either the liver
pathology or the physiological alterations in experimental models of NAFLD will make it difficult to
translate results found in such laboratory model systems to the clinical situation and subsequently the
development of therapeutic or prevention strategies of the disease. Specifically, an appropriate animal
model of NAFLD should display not only steatosis, but also inflammation, liver cell injury (e.g.,
ballooning of hepatocytes) and should, if long enough extended, also progress to fibrosis. Furthermore,
the model should also display metabolic abnormalities like overweight, insulin resistance, impaired